Most Recent Articles about BMY
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL http://www.zacks.com/stock/news/416134/roche-gets-fda-nod-for-venclexta-plus-gazyva-to-treat-cll?cid=CS-ZC-FT-416134 May 17, 2019 - Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid http://www.zacks.com/stock/news/416133/celgene-gets-ec-nod-for-label-expansion-of-revlimid-imnovid?cid=CS-ZC-FT-416133 May 17, 2019 - Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer http://www.zacks.com/stock/news/414385/pfizers-bavencio%2Binlyta-combo-gets-fda-nod-for-kidney-cancer?cid=CS-ZC-FT-414385 May 15, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.

Related Companies

Name Exchange Price Mkt Cap
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
AZN Astrazeneca PLC NYSE $37.56 $95.16B
SNY Sanofi NYSE $43.75 $109.14B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals